Trial Profile

Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Upadacitinib (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms BALANCE-EXTEND
Sponsors AbbVie; AbbVie Germany

15 Jun 2022 Pneumococcal-13-valent-CRM197-vaccine-conjugate has been introduced in the treatment. Primary endpoints amended.
04 Jun 2022 Results assessing final safety and efficacy of UPA in BALANCE-EXTEND, enrolling pts who completed either BALANCE-1 or BALANCE-2 presented at the 23rd Annual Congress of the European League Against Rheumatism
24 May 2022 According to an Abbvie media release, the study data will be presented in European Alliance of Associations for Rheumatology (EULAR) 2022 Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com